Clinical Analysis And Literature Review Of A Case Of Severe Heart Failure Treated With Sacubitril/Valsartan

Background: In recent years,with the rapid development of social economy and medical technology,the survival period of patients with heart disease is prolonged,and the prevalence of heart failure presents an increasing trend.Heart failure remains a major health challenge for countries,with an estimated one in 33 americans suffering from it in the next decade,according to research.At present,activation of the neurohumoral system is believed to be a key factor in the occurrence and development of heart failure,so it is essential to antagonistic the SNS and the RAAS,and to improve the NPS.At present,drug therapy is still the cornerstone of the treatment of heart failure.Sacubitril/valsartan is the first ARNI,the development and successful application of ARNI have opened a new era of drug therapy for heart failure.Objective: To summarize the mechanism of action,research and development process,pharmacokinetic and pharmacodynamic characteristics of ARNI with clinical case and related literature at home and abroad.To strengthen clinicians’ understanding of ARNI,so as to provide reference for clinicians in future related work.Methods: A detailed clinical data of severe heart failure treated with sacubitril/valsartan in the department of cardiology of hebei general hospital is reported.We search the Wanfang Database,CNKI,CBM and Pubmed,with the keywords of “heart failure,sacubitril/valsartan,angiotensin receptor-neprilysin inhibitor”,and summarize relevant literature and case reports.Conclusion: For patients with chronic HFrEF,the administration of sacubitril/valsartan on the basis of conventional treatment can better alleviate the clinical symptoms,improve the cardiac function of patients,and improve the clinical efficacy and the quality of life of patients.